[go: up one dir, main page]

WO2010011117A3 - Composition contenant du ndga pour la suppression de transglutaminase - Google Patents

Composition contenant du ndga pour la suppression de transglutaminase Download PDF

Info

Publication number
WO2010011117A3
WO2010011117A3 PCT/KR2009/004175 KR2009004175W WO2010011117A3 WO 2010011117 A3 WO2010011117 A3 WO 2010011117A3 KR 2009004175 W KR2009004175 W KR 2009004175W WO 2010011117 A3 WO2010011117 A3 WO 2010011117A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
transglutaminase
ndga
present
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2009/004175
Other languages
English (en)
Korean (ko)
Other versions
WO2010011117A2 (fr
Inventor
김수열
이창훈
정경채
이병일
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Cancer Center Japan
National Cancer Center Korea
Original Assignee
National Cancer Center Japan
National Cancer Center Korea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Cancer Center Japan, National Cancer Center Korea filed Critical National Cancer Center Japan
Publication of WO2010011117A2 publication Critical patent/WO2010011117A2/fr
Publication of WO2010011117A3 publication Critical patent/WO2010011117A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une nouvelle utilisation de l'acide nordihydroguaiarétique (NDGA) pour la suppression de transglutaminase. Plus spécifiquement, la présente invention concerne une composition pharmaceutique qui contient de la NDGA en tant que principe actif et qui est utilisée pour la prévention ou le traitement de maladies neurologiques, de maladies inflammatoires et de maladies cancéreuses qui sont des états pathologiques induits par une activité transglutaminase accrue. En outre, la présente invention concerne une méthode dans laquelle ladite composition pharmaceutique est administrée afin de prévenir ou de traiter des maladies neurologiques, des maladies inflammatoires et des maladies cancéreuses induites par une activité transglutaminase. La nouvelle méthode de la présente invention pour supprimer la transglutaminase à l'aide de NDGA est avantageuse en ce qu'elle peut être utilisée de manière sûre et sans effets indésirables chez des sujets présentant des maladies impliquant l'expression anormale de la transglutaminase, et elle peut efficacement traiter ou prévenir lesdites maladies.
PCT/KR2009/004175 2008-07-25 2009-07-27 Composition contenant du ndga pour la suppression de transglutaminase Ceased WO2010011117A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2008-0072912 2008-07-25
KR20080072912 2008-07-25

Publications (2)

Publication Number Publication Date
WO2010011117A2 WO2010011117A2 (fr) 2010-01-28
WO2010011117A3 true WO2010011117A3 (fr) 2010-03-25

Family

ID=41570759

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/004175 Ceased WO2010011117A2 (fr) 2008-07-25 2009-07-27 Composition contenant du ndga pour la suppression de transglutaminase

Country Status (2)

Country Link
KR (1) KR20100011963A (fr)
WO (1) WO2010011117A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107449848A (zh) * 2017-09-22 2017-12-08 完美（中国）有限公司 一种鉴别化妆品原料中拉瑞阿提取物的方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008294A (en) * 1985-02-11 1991-04-16 Chemex Pharmaceuticals, Inc. Methods of treating tumors with compositions of catecholic butanes
US6214874B1 (en) * 1999-10-15 2001-04-10 John Hopkins University Treatment of HPV induced cancer using in situ application of two nordihydroguiaretic acid derivatives, tetramethyl NDGA M4N and tetraglycinal NDGA G4N
WO2003103583A2 (fr) * 2002-06-10 2003-12-18 Oklahoma Medical Research Foundation Procede d'utilisation de bis(polyhydroxyphenyles) et de derives o-alkyle correspondants, fixes, pour le traitement de maladies inflammatoires du systeme nerveux central
US20060141029A1 (en) * 2003-05-20 2006-06-29 Erimos Pharmaceuticals Llc Methods and compositions for delivery of catecholic butanes for treatment of diseases
WO2008042921A2 (fr) * 2006-10-02 2008-04-10 Erimos Pharmaceuticals Llc Dérivés de ndga modifié par pont de butane tétra-o-substitué, leur synthèse et utilisation pharmaceutique

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008294A (en) * 1985-02-11 1991-04-16 Chemex Pharmaceuticals, Inc. Methods of treating tumors with compositions of catecholic butanes
US6214874B1 (en) * 1999-10-15 2001-04-10 John Hopkins University Treatment of HPV induced cancer using in situ application of two nordihydroguiaretic acid derivatives, tetramethyl NDGA M4N and tetraglycinal NDGA G4N
WO2003103583A2 (fr) * 2002-06-10 2003-12-18 Oklahoma Medical Research Foundation Procede d'utilisation de bis(polyhydroxyphenyles) et de derives o-alkyle correspondants, fixes, pour le traitement de maladies inflammatoires du systeme nerveux central
US20060141029A1 (en) * 2003-05-20 2006-06-29 Erimos Pharmaceuticals Llc Methods and compositions for delivery of catecholic butanes for treatment of diseases
WO2008042921A2 (fr) * 2006-10-02 2008-04-10 Erimos Pharmaceuticals Llc Dérivés de ndga modifié par pont de butane tétra-o-substitué, leur synthèse et utilisation pharmaceutique

Also Published As

Publication number Publication date
KR20100011963A (ko) 2010-02-03
WO2010011117A2 (fr) 2010-01-28

Similar Documents

Publication Publication Date Title
WO2009137465A3 (fr) Procédés et compositions pour le traitement ou la prévention d'une remodélisation cardiaque pathologique et d'une insuffisance cardiaque
HK1199726A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MX348705B (es) Composiciones farmacéuticas y métodos de administración relacionados.
PH12012501480A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EP4140487A8 (fr) Polythérapie anticancéreuse
WO2006098603A3 (fr) Composition renfermant de l'isoorientine pour suppression d'histamine
WO2010123569A3 (fr) Composés immunonanothérapeutiques fournissant une réponse à médiation par th1
HK1198619A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MX344329B (es) Formulación de una combinación de dronedarona y ranolazina para la manufactura de un medicamento para tratar fibrilación atrial.
WO2013166177A3 (fr) Combinaison de ptérostilbène et de curcumine pour le traitement du stress oxydatif et de l'inflammation
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
WO2010081091A3 (fr) Compositions thérapeutiques pour le traitement de troubles de la cornée
MX364378B (es) Inhibidores de la quinurenina-3-monooxigenasa, sus composiciones farmaceuticas y metodos para uso.
WO2010028173A3 (fr) Procédé de traitement de fibrillation auriculaire
MY163235A (en) Pharmaceutical preparation containing pyridylaminoacetic acid compound
EP2558102A4 (fr) Interaction synergique d'au moins un constituant de vitamine e et d'inhibiteurs de tyrosinase pour applications dermatologiques
WO2008157747A8 (fr) Utilisation d'inhibition d'exonucléase i dans des procédés de thérapie et de diagnostic de maladies neurodégénératives, de maladies oculaires et de troubles mitochondriaux
WO2009109654A8 (fr) Nouveaux dérivés de 1-benzyl-3-hydroxyméthylindazole et leur utilisation dans le traitement des maladies basées sur l’expression de mcp-1 et cx3cr1
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
WO2008016640A3 (fr) Traitement de l'insuffisance cardiaque progressive chronique
AU2001266289A1 (en) 2-arachidonylglycerol (2-ag) - an inhibitor of tumor necrosis factor -alfa and neuroprotector of brain in closed head injury
WO2007012947A3 (fr) Procede de traitement de lesion d'ischemie-reperfusion
WO2009131850A3 (fr) Inhibiteurs de l’expression et de l’activité de pai-1 pour le traitement des troubles oculaires
WO2019004788A3 (fr) Composition pharmaceutique comprenant de la broussochalcone a à titre de principe actif pour la prévention ou le traitement d'une maladie inflammatoire de l'intestin
WO2008060535A3 (fr) Utilisation de la reversine et de ses analogues pour le traitement du cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09800598

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09800598

Country of ref document: EP

Kind code of ref document: A2